购物车
- 全部删除
- 您的购物车当前为空
Uridine triacetate (RG 2133 triacetate) 是一种具有口服活性的 Uridine 前药。Uridine triacetate 能在肠道内迅速被吸收,在循环中迅速脱乙酰,生成游离尿苷。Uridine triacetate 可用于研究 5-氟尿嘧啶 (5-FU) 和卡培他滨的毒性,或早发性心脏或中枢神经系统 (CNS) 毒性。
Uridine triacetate (RG 2133 triacetate) 是一种具有口服活性的 Uridine 前药。Uridine triacetate 能在肠道内迅速被吸收,在循环中迅速脱乙酰,生成游离尿苷。Uridine triacetate 可用于研究 5-氟尿嘧啶 (5-FU) 和卡培他滨的毒性,或早发性心脏或中枢神经系统 (CNS) 毒性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
50 mg | ¥ 123 | 现货 | |
100 mg | ¥ 163 | 现货 | |
200 mg | ¥ 226 | 现货 | |
500 mg | ¥ 359 | 现货 | |
1 g | ¥ 518 | 现货 | |
5 g | ¥ 1,260 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 179 | 现货 |
产品描述 | Uridine triacetate (RG 2133 triacetate) (Tri-O-acetyl uridine), an orally active prodrug of uridine, is efficiently absorbed in the gut and swiftly deacetylated in the circulation to release free uridine. It is utilized in the research of 5-fluorouracil (5-FU) and capecitabine toxicity, particularly targeting early-onset cardiac or central nervous system (CNS) complications. |
体外活性 | Uridine triacetate inhibits [3H]uridine uptake in ENT1 and ENT2 overexpressed HeLa cells, with IC50s of 28.4 μM and 228.4 μM respectively[4]. |
体内活性 | Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced toxicity in 5-FU overdose mice. Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced 5-FU toxicity in DPD deficiency mice[3]. |
别名 | 尿苷三乙酸酯, Tri-O-acetyluridine, RG2133 triacetate, RG-2133, RG2133, RG 2133 triacetate, RG 2133, PN-401, PN401, PN 401 |
分子量 | 370.31 |
分子式 | C15H18N2O9 |
CAS No. | 4105-38-8 |
Smiles | CC(=O)OCC1OC(C(OC(C)=O)C1OC(C)=O)N1C=CC(=O)NC1=O |
密度 | 1.43 g/cm3 (Predicted) |
存储 | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | H2O: Insoluble DMSO: 90 mg/mL (243 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容